

PATENT

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

10/674480

Bes Tryn. Art Gwyr yr 1975

tubel (U1) is Tubling (F) is take

Mail Stop Patent Application Commissioner of Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: **USA2797 US CNT** INVENTORS: **KLEIN**, **et al**.

TITLE: PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL

DERIVATIVES

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

9/30/2003 Date of Deposit

<u>ÉL 721891925 US</u> Express Mail No.

Signature

APPLICATION ELEMENTS

1.		*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)		:
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	85
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets	
4.	Oath a.	or Declaration Newly executed (original or copy)	Total Pages	2
	b.	Copy from a prior application (37 CFR § 1	I.63(d))	
		i. DELETION OF INVENTOR(S) Signed statement attached deleting application, see 37 CFR §§ 1.63(d)(ned in the prior
5.		er of Attorney	Total Pages	
	a.	Newly executed (original or copy)		
	b.	Copy from a prior application (37 CFR § 1	I.63(d))	
6.		Microfiche Computer Program (Appendix)		

Appl Page	ication Transmittal Letter 2			
7.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)			
	a. Computer Readable Copy			
	b. Paper Copy (identical to computer copy)			
	c. Statement verifying identity of above copies			
	If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no: 09/922,906, filed August 6, 2001, Examiner Chang, Celia C Group/Art Unit 1625. (The cross reference has been/will be inserted on page one of the specification).			
	This application claims the benefit of U.S. Provisional Application No. 60/079,002, filed March 23,1998. (The cross reference has been/will be inserted on page one of the specification).			
\boxtimes	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the pri application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.			
ACC	OMPANYING APPLICATION PARTS			
7.	Assignment Papers (cover sheet & document(s))			
8.	37 CFR §3.73(b) Statement (when there is an assignee)			
9.	Verified English Translation Document (if applicable)			
· 10. :	Information Disclosure Copies of IDS Citations			
	Statement (IDS)/PTO-1449			
11.	Preliminary Amendment			
12.	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)			
13.	*Small Entity Statement(s) (PTO/SB/09-12) Statement filed in prior application, Status still proper and desired			
14.	Certified Copy of Priority Document(s) (if foreign priority is claimed)			
15.	Other: Application Data Sheet – 3 pages Extension of Time For Application No. 09/922,906			
COR	RESPONDENCE ADDRESS			
\boxtimes	Customer Number or Bar Code Label 005487 PATENT TRADEMARK OFFICE			
	Parker, III, Ph.D., Reg. No./34,893			
	Attorney/Agent for Applicant			

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-5674 Telefax (908) 231-2626 Aventis Docket No. **USA2797 US CNT**

Approved for use through 04/30/2003. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 984.00

Complete if Known				
Application Number	Not Yet Assigned			
Filing Date	9/30/2003			
First Named Inventor	KLEIN			
Examiner Name	Chang, Celia C			
Group / Art Unit	1625			
Attornov Docket No.	LICASTOT LIC CNT			

WIETHOU OF PATIVIENT (check all that apply)					.CULATION (continued)	
Check Credit Card Money Other None Order	3. A	DDITIC	NAL F	EES		
Deposit Account	Large Entity Small Entity		ntity			
Deposit	Fee	Fee	Fee	Fee	•	
Account Number 18-1982	Code	(\$)	Code	(\$)		
Denosit					Fee Description Fee Pa	aid
Account Aventis Pharmaceuticals Inc.	1051	130	2051	65	Complement late 600 c. 60	
The Commissioner is authorized to: (check all that apply)	1031	130	2031	65	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or	
Charge fee(s) indicated below Credit any overpayments	1052	50	2052	25	cover sheet	
Charge any additional fee(s) during the pendency of this application	1053	130	1053	130	Non-English Specification	_
Charge fee(s) indicated below, except for the filing fee	1812 1804	2,520 920*	1812 1804	2,520 920*	For filing a request for reexamination	
to the above-identified deposit account	1004	320	1004	920	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE	1251	110	2251	55	Extension for reply within first month	
Large Entity Small Entity Fee						
Fee Fee Fee Fee Fee Description Paid Code (\$) Code (\$)	1252	410	2252	205	Extension for reply within second month	
1001 750 2001 375 Utility filing fee 750	1253	930	2253	465	Extension for reply within third month	
1002 330 2002 165 Design filing Fee	1254	1,450	2254	725	Extension for reply within fourth month	
1003 520 2003 260 Plant filing fee	1255	1970	2255	985	Extension for reply within fifth month	
1004 750 2004 375 Reissue filing fee	1401	320	2401	160	Notice of Appeal	_
1005 160 2005 80 Provisional filing fee	1402	320	2402	160	Filing a briefin support of an appeal	
SUBTOTAL (1) (\$)750.00	1403	280	2403	140	Request for oral hearing	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1451	1,510	. 1451	1,510	Petition to institute a public use	
Fee	1452	110	2452		proceeding	
Extra from Fee	1432	110	2452	55	Petition to revive - unavoidable	
Claims below Paid						
Total Claims 33 -20**= 13 x 18 = 234	1453	1,300	2453	650	Petition to revive - unintentional	- 1
Independent 3 - 3**= x =	1501	1,300	2501	650	Utility issue fee (or reissue)	\dashv
Claims	1502	470	2502	235	Design issue fee	\neg
Multiple Dependent =	1503	630	2503	315	Plant issue fee	\neg
	1460	130	1460	130	Petitions to the Commissioner	_
Large Entity Small Entity Fee Fee Fee Fee	1807	50	1807	50	Petitions related to provisional	
Code (\$) Code (\$) Fee Description					applications	
1202 18 2202 9 Claims in excess of 20	1806	180	1806	180	Submission of Information Disclosure	\dashv
1201 84 2201 42 Independent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	\neg
1203 280 2203 140 Multiple dependent claim, if not paid	1809	750	2809	375	(37 CFR § 1.129(a))	\dashv
1204 84 2204 42 **Reissue independent claims over original patent	1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	\dashv
1205 18 2205 9 **Reissue claims in excess of 20 and over original patent	1801	750	2801	375	Request for Continued Examination (RCE)	\exists
	1802	900	1802	900	Request for expedited examination of a	\dashv
SUBTOTAL (2) (\$)234.00	Other for	(aposi6-)			design application	
30D101AL (2) (φ)234.00	Other fee (specify)					
**or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (5)					

SUBMITTED BY

Name (Print/Type) Raymond S. Parker, III, Ph.D. Reg. No. 34,893 Registration No. (Altomey/Agent)

Signature

Complete (If applicable)

12,638 Telephone (908) 231-5674

Date 9/30/2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/22 (8-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF	TIME UNDER	37 CFR 1.136	Aventis Docket Number USA2797 US CNT		
	In re Application of	KLEIN, et al.			
	Application Number	09/922,906	Filed 6 August 2001		
	For PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES				
	Group Art Unit	1625	Examiner CHANG, Celia C		
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.					
The requested extension fees are as foll (check time period desired):	ows				
One month (37 CFR 1.17	7(a)(1))		\$ 110.00		
Two months (37 CFR 1.1	7(a)(2))		\$ 410.00		
Three months (37 CFR 1	.17(a)(3))		\$ 930.00		
Four months (37 CFR 1.	17(a)(4))		\$ 1,450.00		
Five months (37 CFR 1.1	7(a)(5))		\$ 1,970.00		
The Commissioner has already be application to a Deposit Account.		charge fees in th	is :		
The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 18-1982. I have enclosed a duplicate copy of this sheet.					
I am the assignee of record of	f the entire interest				
applicant.					
attorney or agent of record (Customer No. 005487).					
Date Signature Raymond S. Parker, III, Reg. No. 34,893 Typed or Printed Name					